Investor Overview

Pardes is a clinical-stage biopharmaceutical company created by and for this moment to solve pandemic-sized problems, starting with COVID-19. We are applying modern reversible-covalent chemistry as a starting point to develop novel drugs while reimagining the patient journey to access these medicines.

Stock
Quote

Webcasts

11/15/2022
at 12:00 AM PST
06/09/2022
at 11:30 AM EDT
03/09/2022
at 11:10 AM PST

Financial Information

Document Date Description Form View

Report of unscheduled material events or corporate event

8-K View HTML EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA

Report of unscheduled material events or corporate event

8-K View HTML EX-101.LAB - XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT

Report of unscheduled material events or corporate event

8-K View HTML EX-101.PRE - XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT

Report of unscheduled material events or corporate event

8-K View HTML EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA

Report of unscheduled material events or corporate event

8-K View HTML EX-101.PRE - XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT

Report of unscheduled material events or corporate event

8-K View HTML EX-101.PRE - XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT

Report of unscheduled material events or corporate event

8-K View HTML EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA

Registration statement for face-amount certificate companies

S-1 View HTML

Registration statement for face-amount certificate companies

S-1 View HTML EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA

Registration of up to an additional 20% of securities for any offering registered on an S-1

S-1MEF View HTML

Contact
IR

Send us an investor-related question using the form below.